EP0695169A4 - Liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung - Google Patents
Liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendungInfo
- Publication number
- EP0695169A4 EP0695169A4 EP94916558A EP94916558A EP0695169A4 EP 0695169 A4 EP0695169 A4 EP 0695169A4 EP 94916558 A EP94916558 A EP 94916558A EP 94916558 A EP94916558 A EP 94916558A EP 0695169 A4 EP0695169 A4 EP 0695169A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pct
- cyclodextrin
- pharmacologic
- methods
- pharmacologic compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5113593A | 1993-04-22 | 1993-04-22 | |
US51135 | 1993-04-22 | ||
PCT/US1994/004490 WO1994023697A1 (en) | 1993-04-22 | 1994-04-22 | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0695169A1 EP0695169A1 (de) | 1996-02-07 |
EP0695169A4 true EP0695169A4 (de) | 1998-02-04 |
EP0695169B1 EP0695169B1 (de) | 2002-11-20 |
Family
ID=21969560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94916558A Expired - Lifetime EP0695169B1 (de) | 1993-04-22 | 1994-04-22 | Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung |
Country Status (12)
Country | Link |
---|---|
US (1) | US5759573A (de) |
EP (1) | EP0695169B1 (de) |
JP (1) | JP3545403B2 (de) |
AT (1) | ATE227979T1 (de) |
AU (1) | AU6818094A (de) |
CA (1) | CA2161225C (de) |
DE (1) | DE69431750T2 (de) |
DK (1) | DK0695169T3 (de) |
ES (1) | ES2188612T3 (de) |
HK (1) | HK1013258A1 (de) |
PT (1) | PT695169E (de) |
WO (1) | WO1994023697A1 (de) |
Families Citing this family (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
US5931809A (en) * | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
WO1998026080A1 (en) | 1996-12-13 | 1998-06-18 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6443949B2 (en) * | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
JP4467789B2 (ja) | 1997-09-18 | 2010-05-26 | パシラ ファーマシューティカルズ インコーポレーテッド | 持続放出性リポソーム麻酔組成物 |
EP1900818A3 (de) | 1997-11-06 | 2008-06-11 | Novartis Vaccines and Diagnostics S.r.l. | Neissersche Antigene |
ES2384094T3 (es) | 1997-11-14 | 2012-06-29 | Pacira Pharmaceuticals, Inc. | Producción de liposomas multivesiculares |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
EP2261356A3 (de) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Antigene und Zusammensetzungen gegen Neisseria meningitidis |
US6740643B2 (en) * | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
CN1349402A (zh) * | 1999-03-02 | 2002-05-15 | 利普索姆公司 | 生物活性络合物于脂质体中囊封工艺 |
CA2372235A1 (en) | 1999-04-30 | 2000-11-09 | Rino Rappuoli | Conserved neisserial antigens |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
AUPQ259399A0 (en) | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
EP2975127A1 (de) | 1999-10-29 | 2016-01-20 | GlaxoSmithKline Biologicals SA | Neisseria antigenpeptide |
DE60043197D1 (de) | 1999-11-18 | 2009-12-03 | Univ Kyoto | |
US20070219363A1 (en) * | 1999-11-29 | 2007-09-20 | Budker Vladimir G | Chelating Compound for Drug Delivery |
CN1434706A (zh) | 1999-12-23 | 2003-08-06 | 神经化学公司 | 用于调节脑淀粉状蛋白性血管病的化合物和方法 |
PT1248647E (pt) | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
WO2001066595A2 (en) | 2000-03-08 | 2001-09-13 | Chiron Corporation | Human fgf-23 gene and gene expression products |
EP1950297A2 (de) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
ES2305087T3 (es) | 2000-06-15 | 2008-11-01 | Novartis Vaccines And Diagnostics, Inc. | Polinucleotidos relacionados con el cancer de colon. |
EP2189473A3 (de) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nukleinsäure und Proteine von Gruppen A und B Streptokokken |
US20020160991A1 (en) * | 2000-12-04 | 2002-10-31 | Liming Shao | Orally-bioavailable formulations of fentanyl and congeners thereof |
ES2397627T3 (es) | 2000-12-07 | 2013-03-08 | Novartis Vaccines And Diagnostics, Inc. | Retrovirus endógenos regulados por aumento en el cáncer de próstata |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
AU2002305151A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
BR0102252B1 (pt) * | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
EP1404713A4 (de) | 2001-05-24 | 2004-09-22 | Human Dna Technology Inc | Neues keratinocyte growth factor 2 analogon in haarfollikeln |
FR2827516B1 (fr) * | 2001-07-19 | 2003-09-19 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone |
BRPI0105509B8 (pt) * | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
RU2316591C2 (ru) | 2001-11-09 | 2008-02-10 | Джорджтаун Юниверсити | Новые изоформы ингибитора роста васкулярных эндотелиальных клеток |
NZ546711A (en) | 2001-12-12 | 2008-06-30 | Chiron Srl | Immunisation against chlamydia trachomatis |
EP1472375B1 (de) | 2002-01-08 | 2009-04-01 | Novartis Vaccines and Diagnostics, Inc. | In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren |
JP2005520543A (ja) | 2002-03-21 | 2005-07-14 | サイグレス ディスカバリー, インコーポレイテッド | 癌における新規組成物および方法 |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
JP2005535308A (ja) | 2002-06-13 | 2005-11-24 | カイロン コーポレイション | Hml−2ポリペプチド発現用ベクター |
CA2495899A1 (en) * | 2002-08-15 | 2004-03-18 | Yunqing Liu | Solid nano pharmaceutical formulation and preparation method thereof |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
EP1562982B1 (de) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unerwartete oberflächenproteine in neisseria meningitidis |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
NZ587852A (en) | 2002-12-24 | 2012-02-24 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
EP1592708A2 (de) | 2003-02-14 | 2005-11-09 | Sagres Discovery, Inc. | Therapeutische zielmolekulen von g-protein gekoppelter rezeptor in krebs |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 nsaid를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
ES2426915T3 (es) | 2003-09-10 | 2013-10-25 | Brentwood Equities Ltd. | Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas |
WO2005062955A2 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkc antibodies and methods using same |
DK1736541T3 (da) | 2004-03-29 | 2013-05-06 | Galpharma Co Ltd | Nyt modificeret galectin 9-protein og anvendelse heraf |
PL1732949T3 (pl) | 2004-04-07 | 2010-06-30 | Rinat Neuroscience Corp | Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów |
KR100896697B1 (ko) | 2004-04-09 | 2009-05-14 | (주)아모레퍼시픽 | 고압유화기술에 의한 대황추출물의 경피흡수 촉진방법 및이를 응용한 미백용 피부 외용제 조성물 |
ES2622394T3 (es) | 2004-07-09 | 2017-07-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Formas solubles de la glicoproteína g del virus hendra |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
JP5042828B2 (ja) | 2004-07-30 | 2012-10-03 | ライナット ニューロサイエンス コーポレイション | アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法 |
US7666442B2 (en) * | 2004-08-31 | 2010-02-23 | Tracie Martyn International, Llc | Topical compositions comprising benfotiamine and pyridoxamine |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
ES2385045T3 (es) | 2005-02-18 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Inmunógenos de Escherichia coli uropatogénica |
EP2062591A1 (de) | 2005-04-07 | 2009-05-27 | Novartis Vaccines and Diagnostics, Inc. | CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung |
EP1871911A2 (de) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Gene in verbindung mit krebs (prlr) |
US20070014845A1 (en) * | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
AU2006272713A1 (en) | 2005-07-22 | 2007-02-01 | Y's Therapeutics Co, Ltd. | Anti-CD26 antibodies and methods of use thereof |
US20070055199A1 (en) | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
PL2380592T3 (pl) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals International Gmbh | Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny |
JP2009517402A (ja) * | 2005-11-28 | 2009-04-30 | ディー. ロウェ,バーノン | 腎毒性の低減に有用な組成物及びその使用方法 |
US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
KR100793824B1 (ko) | 2006-03-06 | 2008-01-11 | (주)아모레퍼시픽 | 하이드록시프로필-베타사이클로 덱스트린을 이용하여가용화된 유용성 생리활성성분을 담지하는 고분자-리포좀나노복합체 |
WO2007088476A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
US7935342B2 (en) * | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
SG172684A1 (en) | 2006-06-07 | 2011-07-28 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
AU2007285484B2 (en) | 2006-08-16 | 2013-05-02 | Novartis Ag | Immunogens from uropathogenic Escherichia coli |
US20100261640A1 (en) | 2007-04-10 | 2010-10-14 | Branco Luis M | Soluble and membrane anchored forms of lassa virus subunit proteins |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
KR101499278B1 (ko) | 2007-12-17 | 2015-03-06 | 화이자 리미티드 | 간질성 방광염의 치료 |
CN105732813A (zh) | 2007-12-18 | 2016-07-06 | 生物联合公司 | 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法 |
US20090196917A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions |
EP3023502A1 (de) | 2008-04-10 | 2016-05-25 | Cell Signaling Technology, Inc. | Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
EP2331092B1 (de) | 2008-08-21 | 2014-03-19 | The Johns Hopkins University | Verfahren und zusammensetzungen zur verabreichung von 3-halopyruvat und verwandten verbindungen zur behandlung von krebs |
TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
PE20120169A1 (es) * | 2008-11-17 | 2012-02-29 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
JP5622719B2 (ja) * | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
BRPI1014527B8 (pt) | 2009-03-30 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica na forma de lipossoma e método de fabricação da mesma |
US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
RU2508126C2 (ru) | 2009-04-14 | 2014-02-27 | Новартис Аг | Композиции для иммунизации против staphylococcus aureus |
US20100311838A1 (en) | 2009-05-29 | 2010-12-09 | Pipkin James D | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
CA2768343A1 (en) | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
US9770414B2 (en) * | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
US10610486B2 (en) * | 2010-10-28 | 2020-04-07 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
WO2012118796A1 (en) | 2011-02-28 | 2012-09-07 | The Schepens Eye Research Institute, Inc. | Compositions for controlling neuronal outgrowth |
EP2694031B1 (de) | 2011-04-07 | 2015-07-08 | The Procter and Gamble Company | Haarspülungszusammensetzungen mit erhöhter abscheidung von polyacrylat-mikrokapseln |
WO2012138710A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Personal cleansing compositions with increased deposition of polyacrylate microcapsules |
WO2012138696A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Shampoo compositions with increased deposition of polyacrylate microcapsules |
US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
WO2013028527A1 (en) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions and methods for treating cancer |
CA2954166A1 (en) | 2011-11-11 | 2013-05-16 | Rinat Neuroscience Corp. | Antibodies specific for trop-2 and their uses |
RU2014123030A (ru) | 2011-12-22 | 2016-02-20 | Ринат Ньюросайенс Корп. | Антагонистические антитела против человеческого рецептора гормона роста и способы их применения |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
CN104427976B (zh) | 2012-05-10 | 2018-04-24 | 佩因拉佛姆有限公司 | 疏水的活性成分的储库制剂及其制备方法 |
EP2864360B1 (de) | 2012-06-25 | 2017-09-06 | The Brigham and Women's Hospital, Inc. | Zielgerichtete therapeutika |
CA2877948C (en) | 2012-07-02 | 2019-07-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Paramyxovirus and methods of use |
US20150209281A1 (en) * | 2012-07-18 | 2015-07-30 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
RU2015115956A (ru) | 2012-11-09 | 2017-01-10 | Пфайзер Инк. | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения |
KR20160029731A (ko) | 2013-03-12 | 2016-03-15 | 더 제너럴 하스피탈 코포레이션 | 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도 |
KR20150132473A (ko) | 2013-03-15 | 2015-11-25 | 다이액스 코포레이션 | 항-혈장 칼리크레인 항체 |
CN105189560A (zh) | 2013-05-07 | 2015-12-23 | 瑞纳神经科学公司 | 抗胰高血糖素受体抗体和其使用方法 |
US20170172922A1 (en) * | 2013-05-15 | 2017-06-22 | Hsu-Shen WU | Micron taiwanofungus camphoratus liposome structure |
TWM473835U (zh) * | 2013-05-15 | 2014-03-11 | Wu xu sheng | 微米牛樟芝微脂載體結構 |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
PE20160671A1 (es) | 2013-08-02 | 2016-07-09 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
DK3079712T3 (da) | 2013-12-11 | 2022-04-25 | Massachusetts Gen Hospital | Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse |
WO2015108932A1 (en) * | 2014-01-14 | 2015-07-23 | The Johns Hopkins University | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
WO2015143409A1 (en) | 2014-03-21 | 2015-09-24 | Labrys Biologics, Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
EP3139955B1 (de) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusionsproteine zur behandlung von krebs und zugehörige verfahren |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
CA3219684A1 (en) | 2015-04-13 | 2016-10-13 | Pfizer Inc. | Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3 |
TWM513697U (zh) * | 2015-06-26 | 2015-12-11 | Ma Shen Kai Ruei Co Ltd | 仿生物間質系統的載體結構 |
CA2993026A1 (en) | 2015-07-21 | 2017-01-26 | Dyax Corp. | A monoclonal antibody inhibitor of factor xiia |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
EP3325010B1 (de) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antikörper gegen gerinnungsfaktor xia und verwendungen davon |
NZ739871A (en) | 2015-08-19 | 2022-05-27 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
LT3350220T (lt) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti pro/latentinio miostatino antikūnai ir jų panaudojimas |
NZ741404A (en) | 2015-10-23 | 2024-03-22 | Univ California | Anti-il-2 antibodies and compositions and uses thereof |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
EP3370712A4 (de) | 2015-11-06 | 2019-10-09 | The Johns Hopkins University | Verfahren zur behandlung von leberfibrose durch verabreichung von 3-brompyruvat |
CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
SG11201804961UA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
CN109219618B (zh) | 2016-01-21 | 2022-08-09 | 辉瑞大药厂 | 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途 |
WO2018094253A1 (en) | 2016-11-18 | 2018-05-24 | Pacira Pharmaceuticals, Inc. | Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same |
PE20191487A1 (es) | 2017-03-03 | 2019-10-18 | Rinat Neuroscience Corp | Anticuerpos anti-gitr y metodos de uso de los mismos |
WO2018167621A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
WO2018191548A2 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
KR102505349B1 (ko) | 2017-06-02 | 2023-03-02 | 화이자 인코포레이티드 | Flt3에 특이적인 항체 및 이의 용도 |
US11430545B2 (en) | 2017-06-13 | 2022-08-30 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | ANTI-NUCLEOLIN ANTIBODIES |
EP3692370A2 (de) | 2017-10-04 | 2020-08-12 | OPKO Pharmaceuticals, LLC | Artikel und verfahren zur personalisierten krebstherapie |
EP3706801A4 (de) * | 2017-11-08 | 2022-04-06 | L.E.A.F Holdings Group LLC | Platinkomplexe und verwendungen davon |
CN112020518A (zh) | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
PE20210708A1 (es) | 2018-02-01 | 2021-04-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
US11434292B2 (en) | 2018-05-23 | 2022-09-06 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
AU2019274655B2 (en) | 2018-05-23 | 2023-03-09 | Pfizer Inc. | Antibodies specific for GUCY2c and uses thereof |
MX2021001820A (es) * | 2018-09-14 | 2021-04-28 | Pharmosa Biopharm Inc | Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos. |
CN113490691A (zh) | 2019-01-03 | 2021-10-08 | 劣势者药物有限公司 | 环糊精二聚体、其组合物及其用途 |
CA3146077A1 (en) | 2019-07-03 | 2021-02-18 | Bostongene Corporation | Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
WO2021071830A1 (en) | 2019-10-07 | 2021-04-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP4041773A1 (de) | 2019-10-11 | 2022-08-17 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn-antikörper und verwendungen davon |
US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
WO2021224850A1 (en) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
PE20231565A1 (es) | 2020-07-17 | 2023-10-04 | Pfizer | Anticuerpos terapeuticos y sus usos |
EP4189093A1 (de) | 2020-07-30 | 2023-06-07 | Pfizer Inc. | Zellen mit genduplizierungen und verwendungen davon |
AU2021338361A1 (en) | 2020-09-03 | 2023-04-06 | Chen, Irvin S.Y | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
CN112190498B (zh) * | 2020-10-31 | 2022-03-25 | 华南理工大学 | 一种具有水溶性的茶碱和环糊精包合物及其制备方法 |
US20220180972A1 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
JP2024517745A (ja) | 2021-04-29 | 2024-04-23 | ボストンジーン コーポレイション | 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法 |
CA3227875A1 (en) | 2021-08-02 | 2023-02-09 | Pfizer Inc. | Improved expression vectors and uses thereof |
US20230245479A1 (en) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Machine learning techniques for cytometry |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
WO2024015561A1 (en) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques for detecting homologous recombination deficiency (hrd) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0280503A2 (de) * | 1987-02-23 | 1988-08-31 | Research Development Foundation | Multivesikuläre Liposomen mit einer eingeschlossenen biologisch aktiven Substanz mit einem Hydrochlorid |
WO1992002256A1 (en) * | 1990-08-01 | 1992-02-20 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
WO1993011757A1 (en) * | 1991-12-10 | 1993-06-24 | Orion-Yhtymä Oy | Drug formulations for parenteral use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0261719A3 (de) * | 1986-09-23 | 1990-10-10 | Akzo N.V. | Thermochemischlumineszierende Komplexe von Cyclodextrinen |
US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
-
1994
- 1994-04-22 DK DK94916558T patent/DK0695169T3/da active
- 1994-04-22 JP JP52359394A patent/JP3545403B2/ja not_active Expired - Fee Related
- 1994-04-22 AU AU68180/94A patent/AU6818094A/en not_active Abandoned
- 1994-04-22 ES ES94916558T patent/ES2188612T3/es not_active Expired - Lifetime
- 1994-04-22 AT AT94916558T patent/ATE227979T1/de not_active IP Right Cessation
- 1994-04-22 WO PCT/US1994/004490 patent/WO1994023697A1/en active IP Right Grant
- 1994-04-22 CA CA002161225A patent/CA2161225C/en not_active Expired - Lifetime
- 1994-04-22 DE DE69431750T patent/DE69431750T2/de not_active Expired - Lifetime
- 1994-04-22 US US08/535,256 patent/US5759573A/en not_active Expired - Lifetime
- 1994-04-22 PT PT94916558T patent/PT695169E/pt unknown
- 1994-04-22 EP EP94916558A patent/EP0695169B1/de not_active Expired - Lifetime
-
1998
- 1998-12-22 HK HK98114611A patent/HK1013258A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0280503A2 (de) * | 1987-02-23 | 1988-08-31 | Research Development Foundation | Multivesikuläre Liposomen mit einer eingeschlossenen biologisch aktiven Substanz mit einem Hydrochlorid |
WO1992002256A1 (en) * | 1990-08-01 | 1992-02-20 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
WO1993011757A1 (en) * | 1991-12-10 | 1993-06-24 | Orion-Yhtymä Oy | Drug formulations for parenteral use |
Also Published As
Publication number | Publication date |
---|---|
DE69431750D1 (de) | 2003-01-02 |
HK1013258A1 (en) | 1999-08-20 |
JP3545403B2 (ja) | 2004-07-21 |
ES2188612T3 (es) | 2003-07-01 |
WO1994023697A1 (en) | 1994-10-27 |
EP0695169A1 (de) | 1996-02-07 |
CA2161225C (en) | 2003-07-01 |
JPH08509230A (ja) | 1996-10-01 |
US5759573A (en) | 1998-06-02 |
CA2161225A1 (en) | 1994-10-27 |
DE69431750T2 (de) | 2003-04-03 |
DK0695169T3 (da) | 2003-03-17 |
ATE227979T1 (de) | 2002-12-15 |
EP0695169B1 (de) | 2002-11-20 |
PT695169E (pt) | 2003-04-30 |
AU6818094A (en) | 1994-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0695169A4 (de) | Liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung | |
IL137882A0 (en) | Nanoparticles comprising at least one polymer and at least one compound able to complex one or more active ingredients | |
HUT74548A (en) | Intravaginal delivery system and method for producing it | |
ATE224702T1 (de) | Nichtpolymere verabreichungssysteme mit verzögerter freisetzung | |
ATE228013T1 (de) | Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten | |
PL320167A1 (en) | 2,2-dichloroalkanocarboxylic acids, method of obtaining them and therapeutic agents containing such compounds and their application in treating insulin immunity | |
HK1002017A1 (en) | Lyospheres comprising gonadotropin | |
AU3533395A (en) | Oral sustained-release preparation | |
AU7067594A (en) | A stabilised phenylalanine ammonia lyase | |
ATE374617T1 (de) | Verfahren zur herstellung eines bluddrucksenkenden mittel enthaltenden ein dipeptid als wirksames bestandteil | |
ATE150735T1 (de) | Lagerstabil verkapseltes natriumpercarbonat und verfahren zu seiner herstellung | |
PL320342A1 (en) | Thrombin inhibitor containing infusion solution, stable during storage | |
GR3030197T3 (en) | 2-phase hair treatment medium iii | |
SE9503620D0 (sv) | Användning av proteinet S-100b i läkemedel samt läkemedel innehållande proteinet S-100b | |
PL315619A1 (en) | Oral form of a drug containing acid active substances and method of obtaining same | |
HRP950271A2 (en) | New peptide active substance and the production thereof | |
AU7522398A (en) | Sulfonyloxadiazolones | |
ZA939199B (en) | Methylbutoxy-propionitriles | |
EP0645963A4 (de) | ||
WO2000020441A3 (en) | Cyclic peptides as antifungal agents | |
HUP9701012A2 (hu) | Eljárás izzadásgátló folyadék előállítására, és eljárás pamutalapanyagú fehérnemű izzadásgátló folyadékkal való átitatására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951121 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19971216 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SKYEPHARMA INC. |
|
17Q | First examination report despatched |
Effective date: 20001027 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RTI1 | Title (correction) |
Free format text: MULTIVESICULAR CYCLODEXTRIN LIPOSOMES ENCAPSULATING PHARMACOLOGIC COMPOUNDS AND METHODS FOR THEIR USE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
REF | Corresponds to: |
Ref document number: 227979 Country of ref document: AT Date of ref document: 20021215 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE SA Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69431750 Country of ref document: DE Date of ref document: 20030102 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030400475 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20030219 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2188612 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030821 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20070411 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20070427 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: PACIRA PHARMACEUTICALS, INC. Free format text: SKYEPHARMA INC.#10450 SCIENCE CENTER DRIVE#SAN DIEGO, CA 92121 (US) -TRANSFER TO- PACIRA PHARMACEUTICALS, INC.#10450 SCIENCE CENTER DRIVE#SAN DIEGO, CA 92121 (US) |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PD4A Owner name: PACIRA PHARMACEUTICALS, INC., US Effective date: 20080227 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20080513 Year of fee payment: 15 Ref country code: DK Payment date: 20080430 Year of fee payment: 15 Ref country code: CH Payment date: 20080502 Year of fee payment: 15 |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: PACIRA PHARMACEUTICALS, INC. |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080410 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20080411 Year of fee payment: 15 Ref country code: BE Payment date: 20080616 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20080418 Year of fee payment: 15 Ref country code: IE Payment date: 20080415 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20081022 |
|
EUG | Se: european patent has lapsed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081022 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20080410 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
BERE | Be: lapsed |
Owner name: PACIRA PHARMACEUTICALS INC. Effective date: 20090430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20091101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090422 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090422 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090422 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120510 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20130417 Year of fee payment: 20 Ref country code: DE Payment date: 20130508 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20130625 Year of fee payment: 20 Ref country code: IT Payment date: 20130420 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69431750 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69431750 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20140421 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20140707 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20140421 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20140423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20140423 |